Results 11 to 20 of about 6,021 (252)

Tofacitinib: A Promising Therapeutic Option for Refractory Pityriasis Rubra Pilaris—A Case Report [PDF]

Clinical Case Reports
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder that can severely impact the quality of life in patients, particularly when presenting in chronic or refractory form. Emerging evidence suggests that JAK inhibitors may offer a potential
Mahsa Taremi, Nikoo Mozafari
doaj   +3 more sources

Juvenile Pityriasis Rubra Pilaris [PDF]

Dermatology Practical & Conceptual, 2023
Yihang Xie, Lixia Xie, Xin Shi, Sijia Chen   +3 more
doaj   +4 more sources

Grover's disease-like patterns in early pityriasis rubra pilaris. [PDF]

J Dtsch Dermatol Ges
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 23, Issue 2, Page 231-233, February 2025.
Hoffmann J, Durani B, Hartschuh W.
europepmc   +3 more sources

Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab. [PDF]

JAAD Case Rep, 2023
Saad M, Bose R.
europepmc   +3 more sources

Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab [PDF]

Case Reports in Dermatology, 2018
Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause and often confounded with psoriasis. It is characterised by hyperkeratotic follicular papules, scaly erythematous plaques, palmoplantar keratoderma, and a progression to ...
Kathrin Hanfstingl, Agnes Pekar-Lukacs, Reinhard Motz, Emmanuella Guenova, Wolfram Hoetzenecker   +4 more
doaj   +2 more sources

Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children. [PDF]

Dermatol Ther (Heidelb), 2023
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages, including children. PRP is characterized by follicular and palmoplantar hyperkeratosis and salmon-colored scaling plaques.
Kołt-Kamińska M, Osińska A, Kaznowska E, Reich A.   +3 more
europepmc   +2 more sources

The comprehensive impact of pityriasis rubra pilaris on physical symptoms, mental health, and activities of daily living: A mixed methods study

JEADV Clinical Practice, 2023
Background Pityriasis rubra pilaris (PRP) is a rare and often severe inflammatory skin disorder with major detriment to patients' quality of life. While past studies have described in detail the morphologic and histopathologic presentations of PRP ...
Rose C. Velasco, Brett Cutler, William McCue, Teri M. Greiling   +3 more
doaj   +2 more sources

Drug-related pityriasis rubra pilaris with acantholysis [PDF]

Vojnosanitetski Pregled, 2013
Introduction. Acantholysis is rarely reported histological feature of Pityriasis rubra pilaris (PRP), recently recognized as having diagnostic specificity for differentiating PRP from psoriasis. Case report.
Gajinov Zorica T., Matić Milan B., Duran Verica D., Vučković Nada, Prcić Sonja T., Vujanović Ljuba M.   +5 more
doaj   +3 more sources

Kaposi's Varicelliform Eruption After Treatment With Ixekizumab in a Patient With Pityriasis Rubra Pilaris. [PDF]

Cureus, 2023
Pityriasis rubra pilaris (PRP) is a rare condition characterized by red-orange plaques with islands of sparing with follicular and palmoplantar hyperkeratosis.
Guenther JS, Ahronowitz I, Worswick S.
europepmc   +2 more sources

Delayed Presentation of Pityriasis Rubra Pilaris in a Patient on Treatment With Ponatinib. [PDF]

Cureus
Pityriasis rubra pilaris (PRP) is a rare dermatologic condition whose etiology is largely unknown. However, some medications, including ponatinib, have been implicated. Our case features an 80-year-old patient who developed PRP after two-and-a-half years
Yaldo MM, Olds H, Hengy M, Moossavi M.
europepmc   +2 more sources